Search Within

Department of Medicine

Formats
  1. Journal Article (19593)
  2. Meeting Abstract (16038)
  3. Review (1150)
  4. Book Section (934)
  5. Editorial (610)
  6. Research Letter (314)
  7. Conference Paper (301)
  8. Guidelines (295)
  9. Correspondence (236)
  10. Miscellaneous (90)
  11. Book Whole (61)
Groups
  1. Solid Tumor Oncology Division (22321)
  2. Hematologic Malignancies, Division of (13278)
  3. Center for Hematologic Malignancies (11061)
  4. GSK Faculty (10646)
  5. Survivorship Research (9330)
  6. Division of Subspecialty Medicine (7535)

More Groups

People
  1. Robert Motzer (1248)
  2. Howard Scher (1132)
  3. Sergio Giralt (1069)
  4. Miguel-Angel Perales (943)
  5. Clifford Hudis (905)
  6. Jedd Wolchok (905)

More People

Years
  1. 2025 (1071)
  2. 2024 (2291)
  3. 2023 (2452)
  4. 2022 (2621)
  5. 2021 (2534)
  6. 2020 (2563)

More Years

Publications
  1. Journal of Clinical Oncology (6125)
  2. Blood (3722)
  3. Annals of Oncology (1398)
  4. Cancer Research (1238)
  5. Clinical Cancer Research (902)
  6. Biology of Blood and Marrow Transplantation (679)

More Publications

Publishers
  1. American Society of Clinical Oncology (6458)
  2. Elsevier Inc. (4216)
  3. American Society of Hematology (4003)
  4. American Association for Cancer Research (2896)
  5. Oxford University Press (2286)
  6. Nature Publishing Group (2111)

More Publishers

Results (39622)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Frontline brentuximab vedotin and CHP (A+CHP) in patients (pts) with peripheral T-cell lymphoma with less than 10% CD30 expression: Results from the phase 2 SGN35-032 study
    Meeting Abstract

    Iyer, S. P.; Jagadeesh, D.; Domingo-Domenech, E.; Benedetti, F.; Izquierdo, A. R.; Bouabdallah, K.; Vitolo, U.; Illidge, T. M.; Liu, J.; Shaikh, E.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • DCC-3116 in combination with ripretinib for patients with advanced gastrointestinal stromal tumor: A phase 1/2 study
    Meeting Abstract

    Chandana, S. R.; Shepard, D. R.; Mehnert, J. M.; Chi, P.; Trent, J. C.; Psoinos, C. M.; Zhou, B.; Black, V.; Viswanathan, L.; Gozo, M.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • IDeate-Lung02: A phase 3, randomized, open-label study of ifinatamab deruxtecan (I-DXd) vs treatment of physician's choice (TPC) in relapsed small cell lung cancer (SCLC)
    Meeting Abstract

    Owonikoko, T. K.; Byers, L. A.; Cheng, Y.; Hayashi, H.; Paz-Ares, L. G.; Perol, M.; Turner, J.; Qian, M.; Garcia, C. R.; Godard, J.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • A phase I/II, first-in-human study of VLS-1488, an oral KIF18A inhibitor, in patients with advanced cancer
    Meeting Abstract

    Gaillard, S.; Starodub, A.; O'Neil, B.; Mathews, C. A.; Dumbrava, E. E.; Friedman, C. F.; Swiecicki, P.; Oh, C.; Andreu, C.; Lee, L.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • A first-in-human phase 1, multicenter, open-label study of CB-012, a next-generation CRISPR-edited allogeneic anti-CLL-1 CAR-T cell therapy for adults with relapsed/refractory acute myeloid leukemia (AMpLify)
    Meeting Abstract

    Daver, N. G.; Maiti, A.; Sallman, D. A.; Roboz, G. J.; Solh, M. M.; Milano, F.; Strickland, S. A.; Eghtedar, A.; Kanner, S. B.; Ledergor, G.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Alliance A091902: A multicenter randomized phase II trial of paclitaxel (P) with or without nivolumab (N) in patients (pts) with advanced angiosarcoma (AS)
    Meeting Abstract

    Grilley-Olson, J. E.; Allred, J. B.; Schuetze, S.; Davis, E. J.; Poklepovic, A. S.; Wagner, M. J.; Riedel, R. F.; Hartranft, A.; Welliver, M. X.; Berg, S. A.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Patient factors associated with chemotherapy modifications: Results from the Optimal Breast Cancer Chemotherapy Dosing (OBCD) study
    Meeting Abstract

    Kantor, E.; Bhimani, J.; Gallagher, G. B.; Blinder, V. S.; Burganowski, R. P.; Griggs, J. J.; Kolevska, T.; Kroenke, C.; Laurent, C.; Liu, R.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • A phase 2, open-label, single-arm, prospective, multicenter study of nab-sirolimus plus letrozole in advanced or recurrent endometrioid endometrial cancer
    Meeting Abstract

    Dockery, L. E.; Slomovitz, B. M.; Musa, F.; Mathews, C. A.; Priebe, A. M.; Green, A.; Puechl, A.; Birrer, M. J.; Spirtos, N. M.; Ding, L.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Clinical and translational results from REVOLUTION cohorts A (nivolumab + ipilimumab + chemotherapy) and B (hydroxychloroquine + ipilimumab + chemotherapy) in patients with previously untreated metastatic pancreatic adenocarcinoma
    Meeting Abstract

    O'Reilly, E. M.; Wainberg, Z. A.; Fisher, G. A. Jr; Wolff, R. A.; Ko, A. H.; O'Hara, M. H.; Spencer, C. N.; Yu, J. X.; Da Silva, D. M.; Padron, L. J.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Sotorasib plus panitumumab for pre-treated non-small cell lung cancer with KRASG12C mutation: A phase 1b study
    Meeting Abstract

    Langer, C. J.; Galot, R.; Prenen, H.; Hong, D. S.; Victoria, I.; Salgia, R.; Chenard-Poirier, M.; Furqan, M.; Chan, E.; Nolte-Hippenmeyer, J.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save